Trial Profile
Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Prednisone; Vincristine
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 18 Mar 2013 New trial record